D. Goodin

发表

D. Goodin, 1999 .

Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment?

D. Goodin, 2006, Annals of neurology.

Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis.

Michael R. Johnson, P. Matthews, F. Barkhof, 2009, Human molecular genetics.

Clinical utility of long latency 'cognitive' event-related potentials (P3): the pros.

D S Goodin, D. Goodin, 1990, Electroencephalography and clinical neurophysiology.

Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures.

S J Nelson, D S Goodin, S. Nelson, 2009, Brain : a journal of neurology.

Ovid: Pullman: Neurology, Volume 55(2).July 25, 2000.171-177

D. Goodin, S. Tabbal, S. Pullman, 2006 .

The correlation coefficient and the goodness of fit in source localization of noise recorded by magnetoencephalography

D. Goodin, M. Aminoff, R. Siedenberg, 1996, Brain Topography.

Assessment: Transcranial Doppler ultrasonography: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology*

A. Alexandrov, D. Goodin, D. Newell, 2004, Neurology.

Precision medicine in chronic disease management: The multiple sclerosis BioScreen

Marram P. Olson, R. Henry, D. Goodin, 2014, Annals of neurology.

Title Precision medicine in chronic disease management : The multiple sclerosis

Marram P. Olson, R. Henry, D. Goodin, 2014 .

Spinal cord gray matter atrophy correlates with multiple sclerosis disability

Kesshi M Jordan, R. Henry, D. Goodin, 2014, Annals of neurology.

Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis.

Kesshi M Jordan, R. Henry, D. Goodin, 2015, JAMA neurology.

Atrophy of spinal cord gray matter is detectable at an early stage of multiple sclerosis (S2.003)

Kesshi M Jordan, R. Henry, D. Goodin, 2017 .

Evidence that the long-latency stretch responses of the human wrist extensor muscle involve a transcerebral pathway.

D S Goodin, M J Aminoff, D. Goodin, 1990, Brain : a journal of neurology.

Silent progression in disease activity–free relapsing multiple sclerosis

R. Henry, D. Goodin, E. Caverzasi, 2019, Annals of neurology.

Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis

J L Haines, D S Goodin, J. Haines, 2004, Neurology.

Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis.

C. McCulloch, D. Goodin, E. Waubant, 2015, International journal of MS care.

Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

D S Goodin, D. Goodin, D. Silberberg, 2002, Neurology.

Title : Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis

Kesshi M Jordan, R. Henry, D. Goodin, 2022 .

Detection of epileptiform activity by different noninvasive EEG methods in complex partial epilepsy

D. Goodin, M. Aminoff, K. Laxer, 1990, Annals of neurology.

The Causal Cascade to Multiple Sclerosis: A Model for MS Pathogenesis

Douglas S. Goodin, D. Goodin, 2009, PloS one.

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis

Anthony Traboulsee, Dawn Langdon, D. Goodin, 2011, Journal of Neurology, Neurosurgery & Psychiatry.

Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S.

D. Goodin, G. Cutter, H. Golub, 2014, Multiple sclerosis and related disorders.

Randomized, comparative study of interferon β-1a treatment regimens in MS

D. Goodin, B. Weinshenker, David K.B. Li, 2002, Neurology.

Assessment: Transcranial Doppler ultrasonography: [RETIRED]

A. Alexandrov, D. Goodin, D. Newell, 2004, Neurology.

Organization of sensory discrimination and response selection in choice and nonchoice conditions: a study using cerebral evoked potentials in normal humans.

D. Goodin, M. Aminoff, S. L. Shefrin, 1990, Journal of neurophysiology.

Assessment: Prevention of post–lumbar puncture headaches

D. Goodin, E. Frohman, R. Evans, 2000, Neurology.

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b

Dawn Langdon, Anthony L Traboulsee, Marcelo Kremenchutzky, 2019, Multiple sclerosis.

Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS

D. Goodin, A. Traboulsee, David K.B. Li, 2011, PloS one.

The nature of suprasegmental influences on the late reflex activity in human forearm muscles

D. Goodin, M. Aminoff, R. S. Chequer, 1991, Brain Research.

Recent Advances in Neurology

D. Goodin, E. Waubant, A. Green, 1935, Nature.

Acute hypercalcemia following excessive calcium supplementation in a dehydrated patient with progressive multiple sclerosis: vitamin d supplementation is a red herring-reply.

D. Goodin, S. Josephson, Jacqueline F. Marcus, 2012, Archives of neurology.

Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution.

D. Goodin, S. Josephson, Jacqueline F. Marcus, 2012, Archives of neurology.

Side effect profile of interferon beta-lb in MS

D. Goodin, S. Hauser, D. Goodkin, 1996, Neurology.

Survey of multiple sclerosis in northern California. Northern California MS Study Group.

D. Goodin, 1999, Multiple sclerosis.

Dermatomal somatosensory evoked potentials unilateral lumbosacral radiculopathy

N. Barbaro, D. Goodin, M. Aminoff, 1985, Annals of neurology.

Harnessing electronic medical records to advance research on multiple sclerosis

D. Goodin, P. Villoslada, S. Baranzini, 2019, Multiple sclerosis.

Neuromyelitis Optica

D. Goodin, S. Hauser, B. Cree, 2002, Seminars in neurology.

Evidence-based guideline update: Intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials

R. Emerson, D. Goodin, M. Nuwer, 2012, Neurology.

evoked potentials : Report of the Therapeutics and Technology monitoring with somatosensory and transcranial electrical motor Evidence-based guideline update : Intraoperative spinal

Faan, R. Emerson, D. Goodin, 2012 .

Event-Related Potentials (ERPs)

D. Goodin, 2014 .

Response to interferon beta-1a treatment in African American multiple sclerosis patients.

D. Goodin, A. al‐Sabbagh, R. Bennett, 2005, Archives of neurology.

Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans.

Silke Schmidt, Emmanuel Mignot, Stephen L Hauser, 2004, American journal of human genetics.

The relationship of MS to physical trauma and psychological stress

D. Goodin, J. Wolinsky, G. Ebers, 1999, Neurology.

The relationship between the evoked potential and brain events in sensory discrimination and motor response.

D. Goodin, M. Aminoff, 1984, Brain : a journal of neurology.

Handbook of neurological rating scales

D. Goodin, 1998 .

Reply to “Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS”

R. Henry, D. Goodin, E. Waubant, 2022, Annals of neurology.

READINESS POTENTIAL. REPLY

W. Gehring, D. Goodin, M. Aminoff, 1994 .

The cambridge dictionary of statistics

D. Goodin, 1999 .

D. Goodin, D. Silberberg, F. Lublin, 2002 .

Recommendations Regarding Corticosteroids in the Management of Multiple Sclerosis

D. Goodin, Aaron E Miller, 2008 .

Interleukin 17F level and interferon β response in patients with multiple sclerosis.

D. Goodin, M. Filippi, L. Kappos, 2013, JAMA neurology.

Interferon β treatment for multiple sclerosis

D. Goodin, 1999, The Lancet.

Comparing the efficacy of disease-modifying therapies in multiple sclerosis.

D. Goodin, D. Mitsikostas, 2017, Multiple sclerosis and related disorders.

Reply to Tsivgoulis and colleagues comments.

D. Goodin, D. Mitsikostas, 2018, Multiple sclerosis and related disorders.

The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities

D. Goodin, 2016, BMC Neurology.

The use of MRI in the diagnosis of multiple sclerosis

D. Goodin, 2006, The Lancet Neurology.

Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility

D. Goodin, P. Khankhanian, P. Gourraud, 2018, PloS one.

Disease-modifying therapy in multiple sclerosis

D. Goodin, 2008, Neurology.

Treatment of multiple sclerosis with human beta interferon.

D. Goodin, 2005, International MS journal.

Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures

D. Goodin, E. Mowry, E. Waubant, 2009, Neurology.

Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED]

D. Goodin, J. Stevens, J. Oger, 2007, Neurology.

Dermatomal somatosensory evoked potentials in lumbosacral root compression.

D. Goodin, M. Aminoff, 1988, Journal of neurology, neurosurgery, and psychiatry.

Visual Evoked Potentials

D. Goodin, M. Aminoff, 1994, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

VARIATIONS IN EARLY A N D LATE EVENT-RELATED C O M P O N E N T S OF T H E AUDITORY EVOKED P O T E N T I A L W I T H TASK DIFFICULTY t

D. Goodin, 2002 .

Neurologic Complications of Aortic Disease and Surgery

D. Goodin, 2021, Aminoff's Neurology and General Medicine.

Effect of reference point on visual evoked potentials: clinical relevance.

D S Goodin, M J Aminoff, P Y Shih, 1988, Electroencephalography and clinical neurophysiology.

Treatment with interferon beta for multiple sclerosis.

D. Goodin, G. Cutter, A. Reder, 2012, JAMA.

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

D. Goodin, A. Traboulsee, D. Li, 2010, Journal of Neurology, Neurosurgery & Psychiatry.

Interferon- β Therapy in Multiple Sclerosis

D. Goodin, 2012, Drugs.

HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course.

J. Haines, M. Pericak-Vance, E. Vittinghoff, 2003, American journal of human genetics.

Genetic susceptibility to multiple sclerosis in African Americans

D. Goodin, J. Oksenberg, P. Gourraud, 2021, PloS one.

The nature of genetic and environmental susceptibility to multiple sclerosis

D. Goodin, P. Khankhanian, P. Gourraud, 2021, PloS one.

The epidemiology of multiple sclerosis: insights to a causal cascade.

D. Goodin, 2016, Handbook of clinical neurology.

Haplotype-based approach to known MS-associated regions increases the amount of explained risk

Antoine Lizee, Pierre-Antoine Gourraud, Pouya Khankhanian, 2015, Journal of Medical Genetics.

Single Nucleotide Polymorphism (SNP)-Strings: An Alternative Method for Assessing Genetic Associations

D. Goodin, P. Khankhanian, Pouya Khankhanian, 2014, PloS one.

The epidemiology of multiple sclerosis: insights to disease pathogenesis.

D. Goodin, 2014, Handbook of clinical neurology.

The Genetic and Environmental Bases of Complex Human-Disease: Extending the Utility of Twin-Studies

D. Goodin, 2012, PloS one.

The genetic basis of multiple sclerosis: a model for MS susceptibility

D. Goodin, 2010, BMC neurology.

Title The genetic basis of multiple sclerosis : a model for MS susceptibility Permalink

D. Goodin, 2010 .

Multiple Sclerosis: Exploring the Limits of Genetic and Environmental Susceptibility

D. Goodin, N. Vince, P. Gourraud, 2022, medRxiv.

The pathogenesis of multiple sclerosis

D. Goodin, 2015 .

The Use of Interferon Beta and Glatiramer Acetate in Multiple Sclerosis

D. Goodin, 2013, Seminars in Neurology.

The Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and The MS Council for Clinical Practice Guidelines

D. Goodin, F. Lublin, E. Frohman, 2002 .

Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

D. Goodin, D. Silberberg, S. Noort, 2001 .

Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS

R. Henry, D. Goodin, E. Waubant, 2020, American Journal of Neuroradiology.

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial

D. Goodin, M. Filippi, L. Kappos, 2016, Journal of Neurology.

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b

D. Goodin, M. Filippi, L. Kappos, 2015, Journal of Neurology.

Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States

D. Goodin, G. Cutter, H. Golub, 2014, PloS one.

Survival in MS

D. Goodin, J. Oger, G. Cutter, 2012, Neurology.

Survey of multiple sclerosis in Northern California

D. Goodin, 1999 .

Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis

D. Goodin, E. Waubant, E. Caverzasi, 2021, Annals of neurology.

A comparison of magnetic and electrical stimulation of peripheral nerves

D. Goodin, M. Aminoff, Y. So, 1990, Muscle & nerve.

A comparison of magnetic and electrical stimulation of spinal nerves

D S Goodin, M J Aminoff, D. Goodin, 1990, Muscle & nerve.

Review of the literature on spinal ultrasound for the evaluation of back pain and radicular disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

D. Goodin, 1998, Neurology.

Disease-modifying therapies for multiple sclerosis

D. Goodin, E. Frohman, J. Corboy, 2003, Current treatment options in neurology.

Acute Syphilitic Meningitis: Its Occurrence After Clinical and Serologic Cure of Secondary Syphilis With Penicillin G

D. Goodin, J. Schmidley, L. Bayne, 1986 .

Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED]

D. Goodin, J. Stevens, J. Oger, 2007, Neurology.

Electromyography and Neuromuscular Disorders

D. Goodin, D. S. Goodin, 1998 .

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Ludwig Kappos, Ernst-Wilhelm Radue, Peter A Calabresi, 2014, The Lancet Neurology.

Visual evoked potentials in the investigation of “blindsight”

D. Goodin, M. Aminoff, S. L. Shefrin, 1988, Neurology.

Electrophysiologic evaluation of lumbosacral radiculopathies

D S Goodin, M J Aminoff, N. Barbaro, 1985, Neurology.

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.

D. Goodin, M. Filippi, L. Kappos, 2015, JAMA neurology.

Pilot trial of low‐dose naltrexone and quality of life in multiple sclerosis

D. Goodin, B. Cree, E. Kornyeyeva, 2010, Annals of neurology.

Sequential changes in the P3 component of the auditory evoked potential in confusional states and dementing illnesses

K. Squires, D. Goodin, A. Starr, 1983, Neurology.

Magnetic resonance imaging as a surrogate for treatment effect on multiple sclerosis relapses

D. Arnold, D. Goodin, 2009, Annals of neurology.

Reflection & Reaction Marijuana and multiple sclerosis

D. Goodin, 2005 .

Marijuana and multiple sclerosis

D. Goodin, 2004, The Lancet Neurology.

Thalamic stimulation in essential tremor

D. Goodin, 2004 .

Therapeutic developments in multiple sclerosis

D. Goodin, 2000, Expert opinion on investigational drugs.

An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis

D. Goodin, S. Hauser, W. Stewart, 2020, Multiple sclerosis.

Electrophysiological dfierences between demented and nondemented patients with Parkinson's disease

Michael J. Aminoff, Douglas S. Goodin, D. Goodin, 1987 .

The impact of war‐stress on MS exacerbations

D. Goodin, 2008, Annals of neurology.

Long-latency Cerebral Event-related Potentials in Multiple Sclerosis

D. Goodin, Jonathan C. Aminoff, 2001, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

Cerebral accompaniments to simple and choice reaction tasks in Parkinson's disease

W. Marks, D. Goodin, M. Aminoff, 1998, Brain Research.

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis

D. Goodin, D. Paty, B. Arnason, 2003, Neurology.

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study

D. Goodin, J. Oger, G. Cutter, 2012, BMJ Open.

Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy

E. Vittinghoff, D. Goodin, E. Mowry, 2011, PloS one.

Disease-modifying therapy in MS: a critical review of the literature

D. Goodin, 2004, Journal of Neurology.

Long‐term evolution of multiple sclerosis disability in the treatment era

Alyssa H. Zhu, Nico Papinutto, Stephen L. Hauser, 2016, Annals of neurology.

IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event

D. Goodin, 2006, Neurology.

Incidental MRI anomalies suggestive of multiple sclerosis

D. Goodin, E. Mowry, E. Waubant, 2009, Neurology.

Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review)

D S Goodin, D. Goodin, L. Kappos, 2008, Neurology.

Ambulatory EEG recordings in epileptic and nonepileptic children

D. Goodin, M. Aminoff, B. Berg, 1988, Neurology.

DOES THE INTERICTAL EEG HAVE A ROLE IN THE DIAGNOSIS OF EPILEPSY?

D. Goodin, M. Aminoff, DouglasS. Goodin, 1984, The Lancet.

Assessment: Neuropsychological testing of adults Considerations for neurologists

M. Brin, D. Hanley, D. Goodin, 1996 .

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis

D. Goodin, 2006, Neurology.

Cognitive event-related potentials.

D S Goodin, D. Goodin, 1998, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome

D. Goodin, E. Mowry, E. Waubant, 2011, Neurology.

Glucocorticoid treatment of multiple sclerosis.

D. Goodin, 2014, Handbook of clinical neurology.

The use of immunosuppressive agents in the treatment of multiple sclerosis

D. Goodin, 1991, Neurology.

Randomized, comparative study of interferon &bgr;-1a treatment regimens in MS: The EVIDENCE Trial

D. Goodin, B. Weinshenker, David K.B. Li, 2002 .

Perils and Pitfalls in the Interpretation of Clinical Trials: A Reflection on the Recent Experience in Multiple Sclerosis

D. Goodin, 1999, Neuroepidemiology.

Remote Observational Research for Multiple Sclerosis

D. Goodin, S. Hauser, R. Lincoln, 2022, Neurology: Neuroimmunology & Neuroinflammation.

Interferons in relapsing remitting multiple sclerosis

D. Goodin, 2003, The Lancet.

Magnetic resonance imaging in amyotrophic lateral sclerosis

D. Goodin, H. Rowley, R. Olney, 1988, Annals of neurology.

A comparative analysis of Patient-Reported Expanded Disability Status Scale tools

D. Goodin, L. Kappos, J. Lechner-Scott, 2015, Multiple sclerosis.

CME Assessment : Transcranial Doppler ultrasonography Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology *

A. Alexandrov, D. Goodin, D. Newell, 2004 .

Localizing Dipoles: The Correlation Coefficient and the Goodness of Fit in Source Localization of Filtered Noise

D. Goodin, M. Aminoff, R. Siedenberg, 2000 .

Mortality in patients with multiple sclerosis

D. Goodin, G. Cutter, G. Ebers, 2013, Neurology.

Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies

D. Goodin, M. Filippi, L. Kappos, 2012, Journal of Neuroinflammation.

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

D. Goodin, M. Filippi, L. Kappos, 2012, Multiple sclerosis.

Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS

D. Goodin, A. Traboulsee, D. Li, 2010, Neurology.

Comparison of the effect at 2 years versus placebo on the four major clinical and MRI outcome measures of different doses of interferin b-1a

D. Goodin, R. Rudick, Cook Dl, 1999 .

P300 latency as a biologic marker of dementia

D. Goodin, 1986, Biological Psychiatry.

Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging

G. Fein, J. Tsuruda, D. Goodin, 1994, Annals of neurology.

Chapter 29 – Event-Related Potentials

D. Goodin, 2012 .

Effects of different sensory inputs on the median‐derived somatosensory evoked potential

D S Goodin, M J Aminoff, D. Goodin, 1989, Muscle & nerve.

Recovery of peripheral and central responses to median nerve stimulation.

D S Goodin, M J Aminoff, D. Goodin, 1988, Electroencephalography and clinical neurophysiology.

Order effects in response times of parkinsonian patients and normal controls

W. Marks, D. Goodin, M. Aminoff, 1999, Muscle & nerve.

Retinal Axonal Loss Begins Early in the Course of Multiple Sclerosis and Is Similar between Progressive Phenotypes

D. Goodin, W. Boscardin, A. Green, 2012, PloS one.

In vivo detection of myelin phospholipids in multiple sclerosis with phosphorus magnetic resonance spectroscopic imaging

G B Matson, M W Weiner, D S Goodin, 1994, Annals of neurology.

Chapter 28 – Event-Related Potentials

D. Goodin, 2005 .

Effect of Different High‐Pass Filters on the Long‐Latency Event‐Related Auditory Evoked Potentials in Normal Human Subjects and Individuals Infected with the Human Immunodeficiency Virus

D. Goodin, M. Aminoff, Rosemary S. Chequer, 1992, Journal of clinical neurophysiology.

Electrophysiological evaluation of dementia.

D. Goodin, M. Aminoff, 2008, Handbook of clinical neurology.

Association of Vitamin D LevelsWithMultiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1 b

D. Goodin, M. Filippi, L. Kappos, 2015 .

Results of Using a Wireless Inertial Measuring System to Quantify Gait Motions in Control Subjects

Ruzena Bajcsy, Steven D. Glaser, Iris Tien, 2010, IEEE Transactions on Information Technology in Biomedicine.

Disease-modifying therapy in MS: a critical review of the literature

D. Goodin, 2004, Journal of Neurology.

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.

D. Goodin, David K.B. Li, H. Panitch, 2005, Archives of neurology.

Clinical utility of surface EMG: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

D. Goodin, S. Tabbal, S. Pullman, 2000 .

Changes of forearm EMG and cerebral evoked potentials following sudden muscle stretch in patients with Huntington's disease

D. Goodin, M. Aminoff, R. Siedenberg, 1999, Muscle & nerve.

Changes of forearm EMG and cerebral evoked potentials following sudden muscle stretch during isometric contractions in patients with Parkinson's disease

Michael J Aminoff, D. Goodin, M. Aminoff, 1997, Brain Research.

D S Goodin, M J Aminoff, D. Goodin, 1998, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

D. Goodin, M. Filippi, P. Calabresi, 2004, Neurology.

The utility of MRI in suspected MS

S. L. Galetta, D. Goodin, M. Filippi, 2003, Neurology.

Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis

D. Goodin, E. Havrdová, K. Selmaj, 2007, Current medical research and opinion.

New Frontiers in the Treatment of Multiple Sclerosis : An Evidence-Based Approach Introduction 4 Multiple Sclerosis Overview : Past Versus Present 5 Presenter :

D. Goodin, J. Burks, 2005 .

Comparative studies of glatiramer acetate and interferon beta.

D. Goodin, 2008, International MS journal.

Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre.

D. Goodin, 2006, Journal of neurology.

Relapses in multiple sclerosis: Relationship to disability.

D. Goodin, F. Lublin, Aaron E Miller, 2016, Multiple sclerosis and related disorders.

Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis (P07.102)

D. Goodin, L. Kappos, P. Calabresi, 2013 .

A questionnaire to assess neurological impairment in multiple sclerosis

D S Goodin, D. Goodin, 1998, Multiple sclerosis.

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.

D. Goodin, A. Traboulsee, David K.B. Li, 2009, Clinical therapeutics.

Electrophysiological differences between subtypes of dementia.

D. Goodin, M. Aminoff, 1986, Brain : a journal of neurology.

Overdiagnosis of multiple sclerosis by magnetic resonance imaging

D. Goodin, E. Frohman, 2006, Annals of neurology.

Interferon beta in relapsing-remitting multiple sclerosis

D. Goodin, 2006, Journal of Neurology.

The return of natalizumab: weighing benefit against risk

D. Goodin, 2006, The Lancet Neurology.

Cause of death in MS : long-term own follow-UD of a randornised cohort , 21 years kter the start of the pivotal IFNP-lb study

D. Goodin, A. Reder, S. Cook, 2013 .

Incorporating neutralizing antibody assays into routine clinical practice: a long and arduous road

D. Goodin, 2011, Multiple sclerosis.

K. Squires, D. Goodin, A. Starr, 1979 .

Response to GS Gronseth and E Ashman

D. Goodin, A. Reder, 2012, Multiple sclerosis.

Relationship between multiple sclerosis exacerbations and stress.

D. Goodin, 2004, Psychosomatic medicine.

Cobalt (II) and nickel (II) complexes of phosphoglucomutase.

D. Goodin, W. Ray, L. Ng, 1972, Biochemistry.

Response times and handedness in simple reaction-time tasks

D. Goodin, M. Aminoff, R. S. Chequer, 1996, Experimental Brain Research.

Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients

R. Henry, D. Goodin, S. Baranzini, 2018, Journal of Neuroinflammation.

Electrical brain events associated with awareness of errors

D. Goodin, M. Aminoff, J. Ralph, 2009, Brain Research.

Stimulus recognition and its relationship to the cerebral event-related potential

D. Goodin, M. Aminoff, D. Leppert, 2003, Neurology.

The Decision to Make a Movement: Neurophysiological Insights

D S Goodin, M J Aminoff, D. Goodin, 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution

G. Comi, D. Arnold, D. Goodin, 2011, Neurology.

Comparison of late components in simultaneously recorded event-related electrical potentials and event-related magnetic fields.

D. Goodin, M. Aminoff, R. Siedenberg, 1996, Electroencephalography and clinical neurophysiology.

Expectancy and response strategy to sensory stimuli

D. Goodin, M. Aminoff, Tomás Ortiz, 1993, Neurology.

Multiple sclerosis: Exploring the limits and implications of genetic and environmental susceptibility

D. Goodin, P. Gourraud, N. Vince, 2023, PloS one.

The Nature of Genetic Susceptibility to Multiple Sclerosis

D. Goodin, P. Khankhanian, D. Goodin, 2020, bioRxiv.

Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions

D. Goodin, P. Khankhanian, D. Goodin, 2019, BMC Medical Genomics.

Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions

D. Goodin, P. Gourraud, N. Vince, 2019, BMC Medical Genomics.

Electrophysiologic evaluation of dementia.

D S Goodin, D. Goodin, 1985, Neurologic clinics.

Long latency event-related components of the auditory evoked potential in dementia.

K. Squires, D. Goodin, A. Starr, 1978, Brain : a journal of neurology.

K. Squires, D. Goodin, A. Starr, 1978, Electroencephalography and clinical neurophysiology.

EDSS and MRI burden of disease predict cognitive status at 16 years: data from the long term follow-up study

D. Goodin, A. Traboulsee, David K.B. Li, 2007 .

Electrophysiological assessment of mental function in aging and dementia.

K. Squires, D. Goodin, A. Starr, 1980 .

Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

D. Goodin, D. Silberberg, F. Lublin, 2002, Neurology.

The epidemiology of multiple sclerosis: insights to a causal cascade.

D. Goodin, 2016, Handbook of clinical neurology.

Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

D. Goodin, E. Frohman, S. Noort, 2002, Neurology.

The frontal N30 component of the median‐derived SEP in patients with predominantly unilateral Parkinson's disease

D. Goodin, P. Garcia, M. Aminoff, 1995, Neurology.

ASSESSMENT OF DIGITAL EEG, QUANTITATIVE EEG, AND EEG BRAIN MAPPING

J. Gotman, D. Goodin, W. Sutherling, 2003 .

Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.

D. Goodin, 2001, Drugs.

Dissociating apathy and depression in Parkinson disease

D. Goodin, Y. Cheung, T. Hanafusa, 2006, Neurology.

The Use of Interferon Beta and Glatiramer Acetate in Multiple Sclerosis

D. Goodin, 2013, Seminars in Neurology.

Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode

D. Goodin, D. Goodin, D. Bates, 2009, Multiple sclerosis.

Electrophysiological differences between demented and nondemented patients with Parkinson's disease.

D S Goodin, M J Aminoff, D. Goodin, 1987, Annals of neurology.

Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome

D. Goodin, E. Mowry, E. Waubant, 2011, Neurology.

Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS

D. Goodin, A. Traboulsee, David K.B. Li, 2010, Neurology.

S Matsuoka, H Shibasaki, J F Vibert, 1994, Electroencephalography and clinical neurophysiology.

S Matsuoka, J F Vibert, M R Nuwer, 1994 .

Simple and choice reaction time in Parkinson's disease

Michael J Aminoff, William J Marks, W. Marks, 1999, Brain Research.

Reply from the Authors

D. Goodin, M. Aminoff, P. A. García, 1996, Neurology.

Evidence-Based Guideline Update: Intraoperative Spinal Monitoring with Somatosensory and Transcranial Electrical Motor Evoked Potentials*

D. Goodin, M. Nuwer, A. Legatt, 2012, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

Variations in early and late event-related components of the auditory evoked potential with task difficulty.

K. Squires, D. Goodin, A. Starr, 1983, Electroencephalography and clinical neurophysiology.

Alterations in Multide A-Sclerosis ksions and Normal-appearing White Matter Detected by In Vivo 31 P and ' H Spectroscopic Imaging

G., D. Goodin, G. Matson, 2022 .

Response compatibility and the relationship between event-related potentials and the timing of a motor response.

D. Goodin, M. Aminoff, T. A. Ortiz, 1996, Journal of neurophysiology.

Neural processing in a three-choice reaction-time task: a study using cerebral evoked-potentials and single-trial analysis in normal humans.

D. Goodin, M. Aminoff, T. A. Ortiz, 1993, Journal of neurophysiology.

The utility of MRI in suspected MS

D. Goodin, M. Filippi, P. Calabresi, 2003, Neurology.

The Genetic Basis of Complex Human Disease: Extending the Utility of Twin Studies (P05.123)

D. Goodin, 2012 .

Evaluation of Dementia by Event‐Related Potentials

D. Goodin, M. Aminoff, 1992, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

M R Nuwer, K Maurer, J Desmedt, 1994, Electroencephalography and clinical neurophysiology.

Aberrant STAT phosphorylation signaling in peripheral blood mononuclear cells from multiple sclerosis patients

R. Henry, D. Goodin, S. Baranzini, 2018, Journal of Neuroinflammation.

Interferons in relapsing remitting multiple sclerosis

D. Goodin, L. Kappos, A. Traboulsee, 2003, The Lancet.

The distinction between different types of dementia using evoked potentials.

D. Goodin, M. Aminoff, 1987, Electroencephalography and clinical neurophysiology. Supplement.

Dermatomal somatosensory evoked potentials in lumbosacral root compression.

D. Goodin, M. Aminoff, 1988, Journal of neurology, neurosurgery, and psychiatry.

Sensory Discrimination and its Relationship to the Cerebral Processing of Infrequent Stimuli

D. Goodin, M. Aminoff, M. Mantle, 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Subclasses of event‐related potentials: Response‐locked and stimulus‐locked components

D S Goodin, M J Aminoff, D. Goodin, 1986, Annals of neurology.

Interleukin 17F level and interferon β response in patients with multiple sclerosis.

D. Goodin, M. Filippi, L. Kappos, 2013, JAMA neurology.